PLRX:NASDAQPliant Therapeutics, Inc. analysis
Data as of Oct 22, 2026 - not real-time
- Latest price
- $0.87
- Risk: high
- 9/10High risk
Summary
Pliant Therapeutics, Inc. is priced at $0.8653 and its moving averages line up in bearish order, the shorter trailing the longer. The last 30 days have lost 23.4%. Momentum indicators put RSI at 32.3 (approaching oversold) with MACD reading bearish. Price has been bracketed by support at $0.8510 and resistance at $1.14.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 131.1% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 57.9%, a beta of 1.12 and a maximum drawdown of 52.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 87 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 131.1% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 57.9%, a beta of 1.12 and a maximum drawdown of 52.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 87 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top market events
- Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology...
- Seeking Alpha1yAllogene, Pliant down as J.
- MarketScreener3dPliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.18
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.18
- Analyst targets imply +131.1% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +131.1% versus the current price
- Negative return on equity of -50.3%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-0.7
ROE-50.29%
ROA-23.27%
Debt/Equity19.56
P/B Ratio0.4
Op. Cash Flow$-70895000
Free Cash Flow$-42508876
Industry P/E32.3
Technical analysis
TrendBearish
RSI32.3
Support$0.85
Resistance$1.14
MA 20$0.99
MA 50$1.07
MA 200$1.18
MACDBearish
VolumeStable
Fear & Greed Index87.45
Valuation
Target Price$2.00
Upside/Downside131.13%
GradeUndervalued
TypeBlend
Risk assessment
Beta1.12
Volatility57.87%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.